These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 28068585)
1. Effects of phosphate binders on the gastrointestinal absorption of arsenate and of an SGLT2 inhibitor drug on the urinary excretion of arsenite in mice. Poór M; Németi B; Gregus Z Environ Toxicol Pharmacol; 2017 Jan; 49():179-187. PubMed ID: 28068585 [TBL] [Abstract][Full Text] [Related]
2. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders. Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066 [TBL] [Abstract][Full Text] [Related]
3. Effect of selenite on the disposition of arsenate and arsenite in rats. Csanaky I; Gregus Z Toxicology; 2003 Apr; 186(1-2):33-50. PubMed ID: 12604169 [TBL] [Abstract][Full Text] [Related]
4. Metabolism and excretion of gallium arsenide and arsenic oxides by hamsters following intratracheal instillation. Rosner MH; Carter DE Fundam Appl Toxicol; 1987 Nov; 9(4):730-7. PubMed ID: 3692028 [TBL] [Abstract][Full Text] [Related]
5. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes. van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810 [TBL] [Abstract][Full Text] [Related]
6. Tissue distribution and urinary excretion of inorganic arsenic and its methylated metabolites in mice following acute oral administration of arsenate. Kenyon EM; Del Razo LM; Hughes MF Toxicol Sci; 2005 May; 85(1):468-75. PubMed ID: 15703264 [TBL] [Abstract][Full Text] [Related]
7. Effect of SGLT2 inhibitors in a murine model of urinary tract infection with Candida albicans. Suzuki M; Hiramatsu M; Fukazawa M; Matsumoto M; Honda K; Suzuki Y; Kawabe Y Diabetes Obes Metab; 2014 Jul; 16(7):622-7. PubMed ID: 24400675 [TBL] [Abstract][Full Text] [Related]
8. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice. Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371 [TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Scheen AJ Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma. Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435 [TBL] [Abstract][Full Text] [Related]
11. Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. Tirmenstein M; Dorr TE; Janovitz EB; Hagan D; Abell LM; Onorato JM; Whaley JM; Graziano MJ; Reilly TP Int J Toxicol; 2013; 32(5):336-50. PubMed ID: 24097127 [TBL] [Abstract][Full Text] [Related]
12. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. Katsuno K; Fujimori Y; Takemura Y; Hiratochi M; Itoh F; Komatsu Y; Fujikura H; Isaji M J Pharmacol Exp Ther; 2007 Jan; 320(1):323-30. PubMed ID: 17050778 [TBL] [Abstract][Full Text] [Related]
13. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes. Davidson JA; Kuritzky L Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933 [TBL] [Abstract][Full Text] [Related]
14. Tissue distribution and urinary excretion of dimethylated arsenic and its metabolites in dimethylarsinic acid- or arsenate-treated rats. Adair BM; Moore T; Conklin SD; Creed JT; Wolf DC; Thomas DJ Toxicol Appl Pharmacol; 2007 Jul; 222(2):235-42. PubMed ID: 17559899 [TBL] [Abstract][Full Text] [Related]
15. [Phosphate binder up to date]. Shigematsu T; Sakaguchi T; Orita H Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009 [TBL] [Abstract][Full Text] [Related]
16. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307 [TBL] [Abstract][Full Text] [Related]
17. Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin. Fu Y; Breljak D; Onishi A; Batz F; Patel R; Huang W; Song P; Freeman B; Mayoux E; Koepsell H; Anzai N; Nigam SK; Sabolic I; Vallon V Am J Physiol Renal Physiol; 2018 Aug; 315(2):F386-F394. PubMed ID: 29412698 [TBL] [Abstract][Full Text] [Related]
18. Effect of phosphate transporter and methylation inhibitor drugs on the disposition of arsenate and arsenite in rats. Csanaky I; Gregus Z Toxicol Sci; 2001 Sep; 63(1):29-36. PubMed ID: 11509741 [TBL] [Abstract][Full Text] [Related]